Aequus Pharmaceuticals Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $2.51 million
- Book Value:
- Revenue TTM:
- $1.86 million
- Operating Margin TTM:
- Gross Profit TTM:
- $2.69 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Aequus Pharmaceuticals Inc had its IPO on under the ticker symbol AQSZF.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Aequus Pharmaceuticals Inc has a staff strength of 14 employees.
Shares of Aequus Pharmaceuticals Inc opened at $0.03 at the start of the last trading session i.e. 2023-03-23.
The stocks traded within a range of $0.03 - $0.03, and closed at $0.03.
This is a +40.19% increase from the previous day's closing price.
A total volume of 13,000 shares were traded at the close of the day’s session.
In the last one week, shares of Aequus Pharmaceuticals Inc have increased by +6.38%.
Aequus Pharmaceuticals Inc's Key Ratios
Aequus Pharmaceuticals Inc has a market cap of $2.51 million, indicating a price to book ratio of 32.7765 and a price to sales ratio of 1.4364.
In the last 12-months Aequus Pharmaceuticals Inc’s revenue was $1.86 million with a gross profit of $2.69 million and an EBITDA of $-2437593. The EBITDA ratio measures Aequus Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Aequus Pharmaceuticals Inc’s operating margin was -131.1% while its return on assets stood at -41.77% with a return of equity of -291.74%.
In Q3, Aequus Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 51.1%.
Aequus Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-0.01 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Aequus Pharmaceuticals Inc’s profitability.
Aequus Pharmaceuticals Inc stock is trading at a EV to sales ratio of 1.6318 and a EV to EBITDA ratio of -1.4378. Its price to sales ratio in the trailing 12-months stood at 1.4364.
Aequus Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $2.67 million
- Total Liabilities
- $2.36 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Aequus Pharmaceuticals Inc ended 2023 with $2.67 million in total assets and $0 in total liabilities. Its intangible assets were valued at $2.67 million while shareholder equity stood at $-363789.00.
Aequus Pharmaceuticals Inc ended 2023 with $0 in deferred long-term liabilities, $2.36 million in other current liabilities, 23990904.00 in common stock, $-28698948.00 in retained earnings and $0 in goodwill. Its cash balance stood at $764310.00 and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $28961.00.
Aequus Pharmaceuticals Inc’s total current assets stands at $1.28 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $274896.00 compared to accounts payable of $116509.00 and inventory worth $130106.00.
In 2023, Aequus Pharmaceuticals Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Aequus Pharmaceuticals Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Aequus Pharmaceuticals Inc stock is currently trading at $0.03 per share. It touched a 52-week high of $0.0998 and a 52-week low of $0.0998. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $0.03 and 200-day moving average was $0.04 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 1496.3% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Aequus Pharmaceuticals Inc
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, develops and commercializes drugs in Canada. It focuses on various therapeutic areas, including neurology, ophthalmology, and transplantation. The company markets Vistitan, an ophthalmology product to reduce elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Tacrolimus IR, an immunosuppressant for the treatment and prevention of acute rejection following organ transplantation; Evolve dry eye products for various symptoms involved with dry eye disease and blepharitis, including discomfort, stinging, burning, and dryness; and preservative free ophthalmic product. Its development stage product includes Topiramate XR and Oxcarbazepine XR extended-release oral tablets for the treatment of epilepsy; AQS1303, a transdermal pyridoxine/doxylamine for the treatment of nausea and vomiting of pregnancy; and AQS1304, a cannabinoid based therapeutics for neurological disorders. The company has collaboration agreements with Sandoz Canada, Inc. for the promotion of Vistitan; Supernus Pharmaceuticals, Inc. for marketing of extended-release anti-epileptic drugs; and Medicom Healthcare Ltd. to focus on preservative free therapies in ophthalmology. Aequus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.